Why the study?
Multivalvular disease presents complex interactions among valve pathologies, yet clinical trials and guidelines focus primarily on single-valve disease with few recommendations for multivalvular disease.
This review outlines the emerging percutaneous treatment options and strategies, such as staged transcatheter interventions, for patients with complex multivalvular disease.
Supports staged percutaneous strategies in select multivalvular cases; leaves open need for prospective comparative trials.
Patients with multivalvular disease (MVD) are common and often present with heterogeneous valve defects. Evaluation is complicated by interactions among various valve pathologies. Trials and guidelines focus primarily on single-valve disease, providing few recommendations for the treatment of patients with MVD. This article provides an insight into percutaneous treatment possibilities for this heterogeneous patient population.
No takes yet. Share an insight, caveat, or question.
Erlebach et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: